Dyne Therapeutics, Inc.
NASDAQ:DYNBiotechnology
+$0.38 today
- Market cap
- $2.97B
- Beta
- 1.08
- P/E (TTM)
- -7.2
- EPS (TTM)
- -$2.74
Volume 2.93M
Average 1.71M
DYN Cost of Revenue
Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.
Dyne Therapeutics, Inc.NASDAQ: DYN
Cost of Revenue · Q2 FY2026 · quarter ended Jun 2026
Cost of revenue remains negative
Q2 FY2026 cost of revenue was $0, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $521K.
Context
- Cost of revenue increased in 1 of the last 3 fiscal years.
What to watch
Whether quarterly cost of revenue holds near $0 or moves back toward the trailing-twelve-month quarterly average of $130.25K.
Sources:Income StatementText generated from reported figures; not investment advice.
Cost of Revenue history
USD · from the income statement
- Latest · FY2025
- 2.05M USD
- Year-over-year change
- -8.6%
| Period | Period end | Cost of Revenue | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 2.05M | -8.6% |
| FY2024 | 2024-12-31 | 2.24M | -8.9% |
| FY2023 | 2023-12-31 | 2.46M | — |
| FY2022 | 2022-12-31 | 0 | — |
| FY2021 | 2021-12-31 | 0 | — |
Cost of Revenue vs competitors
How DYN compares with its peers on the latest reported figures
- DYN's LTM Jun 2026 cost of revenue of $521K is the 10th highest of the 11 companies compared; the peer median is $10.75M.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $821.4M | +102.3% | +84.7% | 37.6% | |
| LTM Jun 2026 | $180.19M | +250.5% | +17.1% | 17.9% | |
| LTM Mar 2026 | $42.41M | -26.6% | — | — | |
| LTM Mar 2026 | $40.05M | — | — | 698.0% | |
| LTM Sep 2026 | $17.04M | +44.2% | +4.3% | 1.8% | |
| LTM Mar 2026 | $4.46M | +106.0% | — | 6.2% | |
| LTM Mar 2026 | $3.09M | +178.5% | — | 9.6% | |
| LTM Mar 2026 | $1.72M | +351.6% | — | — | |
| LTM Mar 2026 | $781K | +91.9% | — | — | |
| LTM Jun 2026 | $521K | — | — | — | |
| LTM Mar 2026 | $0 | — | — | — | |
| Peer median (excluding DYN) | $10.75M | +104.1% | +17.1% | 13.7% | |
Competitors are the stored peer set for DYN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 2.46M | 2.24M | 2.05M |
| Gross Profit | 0 | 0 | (2.46M) | (2.24M) | (2.05M) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 121.31M | 142.76M | 210.76M | 281.41M | 398.33M |
| Selling, General & Admin | 28.72M | 28.2M | 31.4M | 62.48M | 69.85M |
| Operating Expenses | 150.03M | 170.96M | 239.7M | 341.64M | 466.14M |
| Depreciation & Amortization | 1.09M | 1.68M | 1.67M | 1.67M | 2.05M |
| EBITDA | (148.2M) | (163.5M) | (234.26M) | (315.75M) | (437.97M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (150.03M) | (170.96M) | (242.16M) | (343.89M) | (468.18M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 742K | 2.92M | 7.64M | 26.92M | 29.86M |
| Interest Expense | 0 | 2.92M | 0 | 0 | 6.19M |
| Other Income / Expenses | 734K | 2.86M | 6.23M | 26.47M | 21.97M |
| Income Before Tax | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (149.29M) | (168.1M) | (235.94M) | (317.42M) | (446.21M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| EPS (Diluted) | (2.93) | (3.23) | (3.95) | (3.37) | (3.47) |
| Weighted Avg Shares | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
| Weighted Avg Shares (Diluted) | 50.9M | 51.98M | 59.68M | 94.14M | 128.44M |
Dyne Therapeutics, Inc.
NASDAQ:DYN
Intrinsic Alpha fair value
Locked
Current Price
$15.87
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.